Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr. Amy Reed, Anti-Power Morcellator Activist, Dead At 44

Executive Summary

Anesthesiologist Amy Reed, who with her cardiologist husband Hooman Noorchasm turned her battle against uterine cancer into a crusade to abolish unsafe uses of power morcellators, died May 24 at her home in Yardley, Pa., at the age of 44.

You may also be interested in...

Pennsylvania Lawmaker Wants Power Morcellators Reviewed In Cancer 'Moonshot' Initiative

Pennsylvania Republican Congressman Mike Fitzpatrick sent a letter to Vice President Joe Biden asking for reforms to medical device review processes, and for a sharper look at power morcellators that he said spreads cancer as part of the administration's cancer "moonshot" initiative.

FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance

FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.

FDA Warns Against Power Morcellators For Uterine Fibroid Surgery

FDA is discouraging use of laparoscopic power morcellation as a therapy for uterine fibroids due to risk of spreading cancer tissue. The agency has instructed manufacturers to ensure that device labeling accurately displays risks; it is planning an advisory panel meeting on the topic for the summer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts